Clinical Diagnosis And Management Of Alzheimer S Disease Third Edition

Owing to the success of the first edition and the rapid development of new drugs for treating Alzheimer's disease, Serge Gauthier has approached not only his original contributors but a number of leading clinicians and researchers to give their views based on clinical experience and scientific evidence for the treatment of this disease.

The third edition of this successful textbook has been completely updated throughout and includes new chapters on electrophysiological tests, biological markers, global staging measures, and management of neuropsychiatric symptoms. There has been steady progress in our understanding of the natural history, prognostic factors and treatments for Alzheimer's disease since the previous edition of this textbook was published in 1999. The chapters deal with the full spectrum of populations at risk, persons in prodromal stages, and patients from mild to severe and even terminal stages. The contributors are opinion leaders from North America and Europe, which gives the book an internationally balanced outlook. This new edition will be essential reading for a wide range of clinical neuroscientists who manage patients with this challenging disease.

A study of the clinical diagnosis and management of Alzheimer's disease. This new edition contains not only the original contributions but a number of clinicians and researchers also give their views based on clinical experience and scientific evidence for the treatment of this disease.

Confusion. Fear. Isolation. This is the human experience of dementing illness, and it is at the heart of this practical, informative volume by a broad range of clinically grounded experts. This book is designed to meet the needs of clinicians dealing with persons with dementing illness and to serve as an introduction to the pathophysiology of dementing illness and a resource for clinical investigators. The giant strides in dementia research since the publication of the first edition in 1991 have generated optimism that we will soon be able to delay onset and even prevent these diseases that devastate both patients and caregivers. This third edition has been revised, updated, and expanded to cover changes in the classification, management and treatment of dementing illnesses and to give a more extensive account of basic and clinical research findings. At the same time, this remarkable volume indicates the interaction of the patient's personality, the caregiver, and the environment with the pathophysiology of dementing illnesses that creates the variety of symptoms accompanying these illnesses and impacting their treatment. Like the second edition, this third edition has three sections, flowing from diagnosis through management/treatment to research. New to this edition are A world-class presentation on the molecular and genetic basis of Alzheimer's disease A beautifully illustrated chapter on contemporary neuroimaging Discussions of mild cognitive impairment, the frontotemporal dementias, and the dementias associated with Lewy bodies This third edition is exceptionally valuable for addressing the day-to-day challenges of dealing effectively and humanely with persons with dementing illness. Case examples are used in the chapters on psychological/behavioral and drug management to indicate practical approaches to maintaining patients at their optimal level of function. Unlike similar texts, this volume also reviews legal and ethical issues in the care of persons with dementing illness and shows how clinicians and caregivers how to mobilize community resources. Extensive reference lists round out each chapter. The book concludes with 11 assessment guides and rating scales and an index. Now more than ever, there is hope that advances in understanding dementing illnesses such as Alzheimer's disease will lead to their effective treatment, and ultimately to their prevention. Until then, clinicians, families, and society will continue to be faced with the challenges posed by these illnesses -- making this book a "must read" for physicians and other health care professionals, whether in training, in practice, or engaged in clinical research.

Now presented in full color, this updated edition of Memory Loss, Alzheimer's Disease, and Dementia is designed as a practical guide for clinicians that delivers the latest treatment approaches and research findings for dementia and related illnesses. Drs. Budson and Solomon - both key leaders in the field - cover the essentials of physical and cognitive examinations and laboratory and imaging studies, giving you the tools you need to consistently make accurate diagnoses in this rapidly growing area. Access in-depth coverage of clinically useful diagnostic tests and the latest treatment approaches. Case studies have been incorporated into the chapters and facilitate the management of both common and uncommon conditions. Comprehensive coverage of hot topics such as chronic traumatic encephalopathy, in addition to new criteria on vascular dementia and vascular cognitive impairment. Includes new National Institute on Aging-Alzheimer's Association and DSM-5 criteria for Alzheimer's Disease and Mild Cognitive Impairment. Learn how to use new diagnostic tests, such as the amyloid imaging scans florbetapir (Amyvid), flutemetamol (Vizamyl), and florbetaben (Neuraceq), which can display amyloid plaques in the living brains of patients. Updated case studies, many complete with videos illustrating common tests, clinical signs, and diagnostic features, are now incorporated into the main text as clinical vignettes for all major disorders. Brand-new chapters on how to approach the differential diagnosis and on primary progressive aphasia. Expert Consult eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, references, and videos from the book on a variety of devices. A practical guide mirroring clinical workflow intended to be used as a tool for accurately diagnosing dementia for all clinicians. Includes case studies and tests.

Differential diagnosis of Alzheimer's disease, dementia and delirium, diagnostic tests in differential diagnosis, and indentifying underlying conditions that can cause dementia are discussed. Covers drugs to treat cognitive symptoms, management of agitation and behavioral symptoms, patient management, and support services

The third edition of this successful textbook has been completely updated throughout and includes new chapters on electrophysiological tests, biological markers, global staging measures, and management of neuropsychiatric symptoms. There has been steady progress in our understanding of the natural history, prognostic factors and treatments for Alzheimer’s disease since the previous edition of this textbook was published in 1999. The chapters deal with the full spectrum of populations at risk, persons in prodromal stages, and patients from mild to severe and even terminal stages. The contributors are opinion leaders from North America and Europe, which gives the book an internationally balanced outlook. This new edition will be essential reading for a wide range of clinical neuroscientists who manage patients with this challenging disease.

In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer’s disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. Alzheimer’s Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD. With contributions from experts drawn from academia, clinical practice, and the biotechnology and pharmaceutical industries, the book explores: The basis of AD and the role of Aβ oligomers in development of disease Existing and emerging in vitro biomarker-based methodologies for the diagnosis of AD, focusing on genetic, biochemical, and conformational strategies In vivo imaging diagnostic approaches Evolving diagnostic criteria, health regulatory guidelines, biomarkers in clinical trials, and available and emerging therapies Recent progress in small-molecule disease-modifier drug discovery efforts for AD, specifically in the areas of Aβ, tau, and emerging neuroprotective/neurorepair approaches How a case study of AD raises issues regarding clinical and pathologic criteria, risk factors, and the amyloid hypothesis The molecular conformational factors that govern the pathogenicity of aggregating proteins, and how these factors could represent new targets for disease-modifying therapies The latest epidemiological, pathological, biochemical, and behavioral studies that may shed some light on the risk of developing AD and similar dementias after traumatic brain injury Examining current hypotheses and suggesting possible new approaches to therapeutic clinical applications, this volume paves the way for a robust pipeline of therapeutics to combat not only AD, but a whole host of other neurodegenerative diseases.